Axogen agreed to acquire Biocircuit Technologies in a $200 million cash transaction, extending the company’s footprint in peripheral nerve repair. The deal brings Nerve Tape, described as the first U.S. FDA-approved device for sutureless nerve repair, into Axogen’s portfolio. For Axogen, the acquisition is designed to deepen adoption in the peripheral nerve market and accelerate expansion of the sutureless technology across new clinical settings. Biocircuit’s commercialization assets also add execution momentum as Axogen positions its broader nerve repair strategy. The move reflects continued consolidation pressure in medtech-adjacent pharma markets, where devices and biologics increasingly intersect in patient pathways and procurement categories. The purchase price—$200 million in cash—also signals Axogen’s willingness to deploy significant capital to strengthen platform breadth in a core specialty area.